臨床婦人科産科70巻11号

2016年11月発行

今月の臨床 骨粗鬆症の最新トピックス─ガイドラインの大幅改訂を迎えて

治療

抗RANKL抗体（デノスマブ）

著者： 安井敏之¹ 松井寿美佳²

所属機関： ¹徳島大学大学院生殖・更年期医療学分野 ²徳島大学大学院産科婦人科学分野

ページ範囲：P.1058 - P.1066

文献概要

●抗RANKL抗体（デノスマブ）はRANKLが受容体に結合するのを競合的にブロックすることにより破骨細胞の分化・活性化を抑制し，骨吸収抑制効果がみられる．

●腰椎，大腿骨近位部，大腿骨頸部，橈骨遠位端1/3など，すべての部位で骨密度の増加が認められる．

●椎体，非椎体，大腿骨近位部，いずれの骨折に対しても有効性が認められている．

●有害事象として，低カルシウム血症，顎骨壊死，非定型大腿骨骨折に注意する．

参考文献

1）大宮俊宣，他 : 骨粗鬆症の薬物療法　抗RANKL抗体．日臨73 : 1659─1663, 2015

2）Cummings SR, et al : Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361 : 756─765, 2009

3）Papapoulos S, et al : The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis : results from the FREEDOM extension study. Osteoporos Int 26 : 2773─2783, 2015

4）Nakamura T, et al : Clinical trial express : fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis : denosumab fracture intervention randomized placebo controlled trial（DIRECT）. J Clin Endocrinol Metab 99 : 2599─2607, 2014

5）Sugimoto T, et al : Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis : results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial（DIRECT）. Osteoporosis Int 26 : 765─774, 2015

6）Brown JP, et al : Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass : a randomized, blinded phase 3 trial. J Bone Miner Res 24 : 153─161, 2009

7）Kendler DL, et al : Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25 : 72─81, 2010

8）Rechnor C, et al : Denosumab compared with ibandronete in postmenopausal women previously treated with bisphosphonate therapy. Obstet Gynecol 12 : 1291─1299, 2013

9）Lin T, et al : Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis : a meta-analysis. Int J Clin Pract 66 : 399─408, 2012

10）宗圓　聡 : 骨粗鬆症の薬剤治療最前線 デノスマブ．日骨粗鬆症会誌2 : 69─73, 2016

11）骨粗鬆症の予防と治療ガイドライン作成委員会 : 骨粗鬆症の治療 デノスマブ．骨粗鬆症の予防と治療ガイドライン2015年版（骨粗鬆症の予防と治療ガイドライン作成委員会 編）．pp118─119，日本骨粗鬆症学会，2015

12）Miller PD, et al : Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy : a randomized blinded phase-2 clinical trial. Bone 43 : 222─229, 2008

13）Brown JP, et al : Discontinuation of denosumab and associated fracture incidence : analysis from the Fracture Reduced Evaluation of Denosumab in Osteoporosis Every 6 Months（FREEDOM） trial. J Bone Miner Res 28 : 746─752, 2013

14）Leder BZ, et al : Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis（The DATA Extension Study） : A randomized controlled trial. J Clin Endocrinol Metab 99 : 1694─1700, 2014

15）Tsai JN, et al : Comparative effects of teriparatide, denosumab and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength : the DATA-HR-pQCT Study. J Bone Miner Res 30 : 39─45, 2015

16）Leder BZ, et al : Denosumab and teriparatide transitions in postmenopausal osteoporosis（the DATA-Switch Study） : extension of a randomized controlled trial. Lancet 386 : 1147─1155, 2015

17）Passeri E, et al : A single 60 mg dose of denosumab might improve hepatic insulin sensitivity in postmenopausal nondiabetic severe osteoporotic women. Int J Endocrinol 2015 : 352858, 2015

18）Samelson EJ, et al : RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res 29 : 450─457, 2014

19）Wu M, et al : Vascular calcification : an update on mechanisms and challenges in treatment. Calcif Tissue Int 93 : 365─373, 2013